Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design

Scandinavian Cardiovascular Journal

Volumn 34, Issue 2, 2000, Pages 168-171

  Hurlen, M ^a   Smith, P ^a   Arnesen, H ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aspirin; Myocardial infarction; Secondary prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALBYL E; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FIBRINOLYTIC THERAPY; GASTROINTESTINAL TOXICITY; HEART REINFARCTION; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCREENING; THROMBOEMBOLISM;

EID: 0034460484     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430050142198     Document Type: Article

References (35)

1. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi
2. The relationship between coronary artery lesions and myocardial infarcts: Ulceration of atherosclerotic plaques precipitating coronary thrombosis
3. Coronary thrombosis in pathogenesis of acute myocardial infarction: Histopathological study of coronary arteries in 108 necropsied cases using serial section
4. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
5. Deaths and non-fatal reinfarctions during two years' follow-up after myocardial infarction
6. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
7. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction
8. Anticoagulant therapy after acute myocardial infarction
9. Anticoagulants in acute myocardial infarction: The failure of anticoagulants to alter mortality in randomized series
10. A double-blind trial of long-term anticoagulant treatment after myocardial infarction
11. Double blind trial of long-term anti-coagulant treatment after myocardial infarction
12. Anticoagulant treatment of acute coronary thrombosis
13. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction
14. The effect of warfarin on mortality and reinfarction after myocardial infarction
15. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
16. Aspirin and secondary mortality after myocardial infarction
17. Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin
18. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
19. Secondary prevention of myocardial reinfarction. A comparison of acetylsalicylic acid, placebo and phenprocoumon
20. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
21. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomised clinical trial
22. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole
23. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet activity after aortic valve replacement
24. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
25. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
26. Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects
27. Aspirin and the stomach
28. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: A study in 3166 outpatients
29. Power/sample size calculations for generalized linear models
30. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial
31. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
32. Power calculations for likelihood ratio tests in generalized linear models
33. An efficient and portable pseudo-random number generator
34. Nomenclature and criteria for diagnosis of ischemic heart disease: Report of the joint international society and federation of cardiology/world health organization task force on standardization of clinical nomenclature